These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27684210)

  • 1. In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib.
    McCormick A; Swaisland H
    Xenobiotica; 2017 Oct; 47(10):903-915. PubMed ID: 27684210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K).
    Kikuchi R; Lao Y; Bow DA; Chiou WJ; Andracki ME; Carr RA; Voorman RL; De Morais SM
    J Pharm Sci; 2013 Dec; 102(12):4426-32. PubMed ID: 24122511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
    Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
    Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of
    Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
    Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
    Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
    Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of
    Parvez MM; Shin HJ; Jung JA; Shin JG
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223391
    [No Abstract]   [Full Text] [Related]  

  • 7. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
    Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
    Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of bilastine, a new oral H₁ antihistamine, with human transporter systems.
    Lucero ML; Gonzalo A; Ganza A; Leal N; Soengas I; Ioja E; Gedey S; Jahic M; Bednarczyk D
    Drug Chem Toxicol; 2012 Jun; 35 Suppl 1():8-17. PubMed ID: 22616811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.
    Durmus S; Lozano-Mena G; van Esch A; Wagenaar E; van Tellingen O; Schinkel AH
    Mol Pharm; 2015 Dec; 12(12):4259-69. PubMed ID: 26474710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions Between Meropenem and Renal Drug Transporters.
    Dong J; Liu Y; Li L; Ding Y; Qian J; Jiao Z
    Curr Drug Metab; 2022 Aug; 23(5):423-431. PubMed ID: 35490314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
    Ebner T; Ishiguro N; Taub ME
    J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
    Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
    Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid.
    Ren G; Qin Z; Yang N; Chen H; Fu K; Lu C; Lu Y; Li N; Zhang Y; Chen X; Zhao D
    Chem Biol Interact; 2020 Jun; 324():109097. PubMed ID: 32305507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.
    Yu RZ; Warren MS; Watanabe T; Nichols B; Jahic M; Huang J; Burkey J; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2016 Apr; 26(2):111-7. PubMed ID: 26959999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.
    Hanna I; Alexander N; Crouthamel MH; Davis J; Natrillo A; Tran P; Vapurcuyan A; Zhu B
    Xenobiotica; 2018 Mar; 48(3):300-313. PubMed ID: 28281384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3.
    Gozalpour E; Greupink R; Wortelboer HM; Bilos A; Schreurs M; Russel FG; Koenderink JB
    Mol Pharm; 2014 Jun; 11(6):1844-55. PubMed ID: 24754247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.
    Oshida K; Shimamura M; Seya K; Ando A; Miyamoto Y
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):117-128. PubMed ID: 26961540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo.
    Song IS; Kong TY; Jeong HU; Kim EN; Kwon SS; Kang HE; Choi SZ; Son M; Lee HS
    BMC Complement Altern Med; 2014 Jul; 14():251. PubMed ID: 25034211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir.
    Kosloski MP; Bow DAJ; Kikuchi R; Wang H; Kim EJ; Marsh K; Mensa F; Kort J; Liu W
    J Pharmacol Exp Ther; 2019 Aug; 370(2):278-287. PubMed ID: 31167814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug-drug interactions via these transporters.
    Takanohashi T; Kubo S; Arisaka H; Shinkai K; Ubukata K
    J Pharm Pharmacol; 2012 Feb; 64(2):199-206. PubMed ID: 22221095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.